Does one size fit all? An update on chronic ventilatory support in different respiratory illnesses.
Annalisa CarlucciMaxime PatoutJoao-Carlos WinckPublished in: Breathe (Sheffield, England) (2023)
Home noninvasive ventilation (HNIV) improves outcomes in different disease categories. In this article, we discuss indications for when and how to initiate HNIV in COPD, obesity hypoventilation syndrome (OHS) and neuromuscular disorders (NMD). While in COPD, significant diurnal hypercapnia and high-intensity HNIV are essential ingredients for success, in NMD and OHS, early respiratory changes are best detected during sleep through oxy-capnography associated (or not) with respiratory polygraphy. In COPD and OHS, it is crucial to consider the coexistence of obstructive sleep apnoea because treatment with continuous positive airway pressure may be the simplest and most effective treatment that should be proposed even in hypercapnic patients as first-line therapy. In NMD, the need for continuous HNIV and eventual switching to tracheostomy ventilation makes this group's management more challenging. Achieving successful HNIV by improving quality of sleep, quality of life and keeping a good adherence to the therapy is a challenge, above all in COPD patients. In OHS patients, on top of HNIV, initiation of other interventions such as weight loss management is crucial. More resources should be invested in improving all these aspects. Telemonitoring represents a promising method to improve titration and follow-up of HNIV.
Keyphrases
- end stage renal disease
- chronic obstructive pulmonary disease
- weight loss
- ejection fraction
- high intensity
- chronic kidney disease
- positive airway pressure
- newly diagnosed
- obstructive sleep apnea
- physical activity
- peritoneal dialysis
- type diabetes
- bariatric surgery
- prognostic factors
- lung function
- insulin resistance
- metabolic syndrome
- body mass index
- bone marrow
- intensive care unit
- patient reported outcomes
- body composition
- respiratory failure
- air pollution
- mesenchymal stem cells
- replacement therapy
- drug induced